Breast Implant–Associated Anaplastic Large-Cell Lymphoma: Current Understanding and Recommendations for Management

Abstract

Worldwide, millions of women live with breast implants. Therefore, it is important that physicians be aware of an uncommon but possibly serious complication arising from breast implants: breast implant–associated anaplastic large cell lymphoma (BIA-ALCL). Breast implant–associated anaplastic large-cell lymphoma most commonly presents as a delayed fluid collection around a textured breast implant or as a mass in the capsule surrounding the implant. The exact pathogenesis of the disease remains unclear. The neoplastic cells of BIA-ALCL show strong uniform staining for CD30 and are consistently negative for activin receptor-like kinase 1. Patients with confirmed cases should be referred to a lymphoma specialist or breast medical oncologist for a complete oncologic evaluation before any surgical intervention. For disease confined to the fluid accumulation or capsule, or both, surgical removal of the implant and complete capsulectomy is the preferred treatment. Postoperative chemotherapy or radiation, or both, are not considered necessary for patients with limited-stage disease and are reserved for advanced disease stages. Generally, BIA-ALCL is a local disease that follows an indolent course and has an excellent prognosis. Although complete remission of disease has occurred in patients with BIA-ALCL, median overall survival is reduced. As of March 2018, approximately 529 unique, confirmed BIA-ALCL cases had been reported in 23 countries. To date, 16 patients have died from BIA-ALCL, and all had extracapsular involvement. The aim of this article is to summarize the diagnosis, evaluation, and management of BIA-ALCL, based on established guidelines, for all practitioners who may care for patients with breast implants.

Linfoma anaplásico de células gigantes asociado a implantes mamarios, una enfermedad desconocida

“…En este examen debe evaluarse la membrana del implante (que puede presentar contornos irregulares), la cápsula (que se puede observar adelgazada), el parénquima adyacente mamario, la cadena ganglionar axilar y el implante contralateral (47,48). Hay que tener en cuenta que los hallazgos más comunes en los pacientes con diagnóstico de LACG-AIM en el ultrasonido son, en primer lugar, la colección periprotésica (Figuras 2 y 3) en el 84 % de los casos y, en segundo lugar, la evidencia de una masa en el 46 %, de acuerdo con Adrada et al (47).…”

Silicone Particle Migration: A Misleading Report

“…With the exception of the extremely rare breast implant–associated anaplastic large cell lymphoma, none of these associations have been substantiated in thorough epidemiologic investigations. 2 , 3 Nevertheless, the authors conclude their report with a call for an immediate ban on the utilization of all SBIs. We believe this appeal to result from a non sequitur.…”

Breast Implant Anaplastic Large Cell Lymphoma (BIA- ALCL): A Systematic Review and Case Report Regarding Incidence and Pathology Workup

“…This eventually led to the possibility of more precise diagnostic and therapeutic recommendations of this rare, indolent yet lethal disease 11 . Today an interdisciplinary approach with early, specific detection proved to be associated with an excellent prognosis 12 . The diagnostic pathway now consists of clinical presentation, medical imaging, and pathologic workup 13 .…”